Nutralife Biosciences Inc
NutraLife BioSciences, Inc., together with its subsidiaries, engages in the development, manufacture, and distribution of nutraceutical, dietary, wellness, and cannabidiol (CBD) products. Its CBD products include cannabinoid-rich hemp oil derived from industrial hemp; tinctures; topical lotions and oils applied directly to the skin to treat pain or inflammation; face creams; massage oils; nutrace… Read more
Nutralife Biosciences Inc (NLBS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2022: 0.190x
Based on the latest financial reports, Nutralife Biosciences Inc (NLBS) has a cash flow conversion efficiency ratio of 0.190x as of September 2022.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-439.96K) by net assets ($-2.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nutralife Biosciences Inc - Cash Flow Conversion Efficiency Trend (2012–2021)
This chart illustrates how Nutralife Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nutralife Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nutralife Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
THROMBOGENICS
BE:TG4
|
N/A |
|
122830
KO:122830
|
N/A |
|
PTS Inc
PINK:PTSH
|
-0.021x |
|
Lake House Printers and Publishers PLC
CM:LPRTN0000
|
N/A |
|
QRT
WAR:QRT
|
N/A |
|
Central Finance Company PLC
CM:CFINN0000
|
N/A |
|
Jr Global Reit
KO:348950
|
N/A |
|
KST BETEILIG N (KSW.SG)
STU:KSW
|
N/A |
Annual Cash Flow Conversion Efficiency for Nutralife Biosciences Inc (2012–2021)
The table below shows the annual cash flow conversion efficiency of Nutralife Biosciences Inc from 2012 to 2021.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2021-12-31 | $-712.53K | $-487.39K | 0.684x | +116.04% |
| 2020-12-31 | $301.11K | $-1.28 Million | -4.265x | -130.97% |
| 2019-12-31 | $1.59 Million | $-2.93 Million | -1.847x | -541.50% |
| 2018-12-31 | $815.25K | $-234.67K | -0.288x | +81.32% |
| 2017-12-31 | $660.52K | $-1.02 Million | -1.541x | -159.89% |
| 2016-12-31 | $-260.79K | $-671.15K | 2.574x | -45.34% |
| 2015-12-31 | $-180.68K | $-850.68K | 4.708x | +263.07% |
| 2014-12-31 | $-949.33K | $-1.23 Million | 1.297x | -89.78% |
| 2013-12-31 | $-71.10K | $-902.49K | 12.693x | +628.94% |
| 2012-12-31 | $-167.10K | $-290.98K | 1.741x | -- |